Sacubitril/valsartan in PARADIGM-HF - Authors' reply

Lancet Diabetes Endocrinol. 2017 Jul;5(7):496. doi: 10.1016/S2213-8587(17)30179-1.

Authors

Jelena P Seferovic¹, Brian Claggett¹, Scott D Solomon²; PARADIGM-HF investigators

Affiliations

¹ Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston MA, 02115, USA.
² Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston MA, 02115, USA. Electronic address: ssolomon@bwh.harvard.edu.

PMID: 28645439
DOI: 10.1016/S2213-8587(17)30179-1

No abstract available

Publication types

Letter
Comment

MeSH terms

Aminobutyrates*
Angiotensin Receptor Antagonists
Biphenyl Compounds
Drug Combinations
Heart Failure
Humans
Tetrazoles*
Valsartan

Substances

Aminobutyrates
Angiotensin Receptor Antagonists
Biphenyl Compounds
Drug Combinations
Tetrazoles
Valsartan
sacubitril and valsartan sodium hydrate drug combination